NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundTo identify genetic loci associated with Parkinson's disease (PD) through a genome-wide meta-analysis, to screen for druggable genes significantly linked to PD risk, and evaluate their potential as therapeutic targets.MethodsData from DGIdb, GeneCards, and the Finan genomic resource were integrated to identify candidate therapeutic genes associated with PD. Genome-wide meta-analysis was conducted using GWAS data from the International Parkinson's Disease Genomics Consortium and FinnGen, involving 1,851,374 participants. Mendelian randomization (MR), colocalization analysis, and phenome wide association studies (PheWAS) were conducted to validate the associations between the identified genes and PD. Furthermore, knockout mouse models from the Mouse Genome Informatics were analyzed to validate PD-related phenotypes, and DSigDB was utilized to predict potential therapeutic compounds.ResultsWe identified several therapeutic genes significantly associated with PD risk. Colocalization analysis suggested shared causal genetic variants between these genes and PD. PheWAS further revealed that GCLC and GFPT1 exhibit limited pleiotropic effects across other traits. Eight potential compounds were identified through DSigDB predictions.ConclusionThrough genome-wide meta-analysis, MR, colocalization, and PheWAS, we identified genetic loci associated with PD and assessed GCLC and GFPT1 as potential therapeutic targets.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.